In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Galapagos (GLPG). The company’s shares closed last Tuesday at $128.02, close to its 52-week low of $112.00.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 9.7% and a 46.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Currently, the analyst consensus on Galapagos is a Hold with an average price target of $141.96, which is a 10.0% upside from current levels. In a report issued on October 13, Barclays also maintained a Hold rating on the stock with a EUR125.00 price target.
See today’s analyst top recommended stocks >>
Galapagos’ market cap is currently $8.32B and has a P/E ratio of 87.00. The company has a Price to Book ratio of 2.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Read More on GLPG:
